PRKAA1

Overview

PRKAA1 encodes the catalytic alpha-1 subunit of AMP-activated protein kinase (AMPK), a central cellular energy sensor that helps maintain metabolic homeostasis. AMPK is activated when cellular energy is low and coordinates adaptive responses that promote ATP-generating processes while restraining energy-consuming pathways. Through this role, PRKAA1 is biologically linked to regulation of glucose and lipid metabolism, mitochondrial function, autophagy, inflammation, and stress adaptation.

In biomedical research, PRKAA1 is frequently discussed in the context of diseases and processes shaped by metabolic stress, including cancer, liver disease, adipocyte catabolism, myocardial ischemia/reperfusion injury, neuroinflammation, aging, and autophagy-related disorders. It is also a recurring target in studies of natural products, small-molecule modulators, and pathway-based therapies that intersect with PI3K/AKT/mTOR, sirtuin 1, TGF-β/Smad, and PD-1/PD-L1 signaling.

Recent Publications Focus

Below is a summary of the newest research publications targeting PRKAA1 (sorted by publication date).

Recent studies continue to place PRKAA1, the catalytic subunit of AMP-activated protein kinase (AMPK), at the center of metabolic, inflammatory, and stress-response signaling. In an Alzheimer's disease model, resveratrol was reported to improve cognitive impairment in Aβ1-42-induced mice, reduce aging-related markers, and attenuate reactive oxygen species production in vitro. The authors linked these effects to activation of autophagy-associated signaling, with mechanistic involvement of the AMPK/ULK1 and SIRT1/NF-κB pathways. In a separate diabetic encephalopathy study, berberine and metformin were combined and shown to produce supra-additive recovery of recognition memory, with the strongest mechanistic correlate being suppression of neuroinflammatory endpoints; the authors also observed AMPK activation and noted that the AMPK-Nrf2 axis remained correlative pending direct validation.

PRKAA1 was also implicated in broader metabolic regulation and energy balance. A nutrient-responsive AMPK/TBK1 circuit was described in adipocytes, where fasting or pharmacological AMPK activation induced Tbk1 transcription and TBK1 then limited AMPK activity through a feedback cascade. In obesity, this axis was disrupted, and adipocyte-specific TBK1 deletion enhanced fasting-induced AMPK activation, mitochondrial function, and lipolytic gene expression. Pharmacological TBK1 inhibition with amlexanox reproduced these effects, and combining amlexanox with the AMPK activator AICAR improved weight loss, glucose tolerance, insulin sensitivity, and inflammatory and lipogenic programs. Another study identified Feimin as an AMPK-dependent regulator of cold-induced thermogenesis: AMPK phosphorylated Feimin, promoting its nuclear translocation and interaction with PGC1α to drive thermogenic gene expression, whereas Feimin loss abolished cold-induced thermogenesis and worsened diet-induced obesity.

Additional publications linked PRKAA1-associated signaling to inflammation, developmental programming, and cancer. Maternal broccoli powder intake during lactation increased AMPK phosphorylation in the liver and hypothalamus of weaning rats programmed by maternal protein restriction, while reducing macrophage and microglial markers, NF-κB p65, and TNF-α expression and lowering mTOR and Akt phosphorylation in the liver. In primary liver cancer models, sophoricoside inhibited proliferation, migration, and invasion, increased AMPK phosphorylation, and reduced tumor growth and Ki67 expression in xenografts; these effects were lost with the AMPK inhibitor compound C, supporting AMPK dependence. In pancreatic ductal adenocarcinoma, irinotecan-induced early AMPK activation was shown to drive autophagy and fatty acid oxidation, contributing to acquired drug resistance, and blocking fatty acid oxidation restored cytotoxicity and prevented tumor regrowth in vivo.

Recent reviews further reinforced the centrality of AMPK in aging, autophagy, and neurodegeneration. One review discussed neuroinflammation and autophagy dysregulation in Alzheimer's, Parkinson's, and Huntington's diseases, highlighting AMPK and mTOR as key regulatory nodes. Another reviewed ovarian aging and described AMPK among the major longevity pathways implicated in follicular activation, granulosa cell apoptosis, and oocyte quality decline. A broader review of bioactive natural products emphasized that compounds such as resveratrol, flavonoids, alkaloids, terpenoids, and carotenoids can modulate autophagy through AMPK, PI3K/AKT/mTOR, SIRT1, and FOXO signaling, underscoring the continued interest in PRKAA1-linked pathways as therapeutic targets across aging-related and metabolic diseases.

Background PMIDs

• [PMID 41671772]

Target PMIDs

• [PMID 41690450]
• [PMID 41740333]
• [PMID 41811567]
• [PMID 41830033]
• [PMID 41831381]
• [PMID 41833148]
• [PMID 41918200]
• [PMID 42003007]
• [PMID 42008004]
• [PMID 42036778]
• [PMID 42066046]
• [PMID 42100877]
• [PMID 42390621]
• [PMID 42412302]

Conclusion PMIDs

• [PMID 41833273]